DYN

Dyne Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.00
-0.06
-0.27%
After Hours: 22.00 0 0.00% 16:00 09/25 EDT
OPEN
22.05
PREV CLOSE
22.06
HIGH
22.87
LOW
21.79
VOLUME
189.33K
TURNOVER
--
52 WEEK HIGH
27.11
52 WEEK LOW
21.07
MARKET CAP
915.94M
P/E (TTM)
-34.0716
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dyne Therapeutics Announces Pricing of Initial Public Offering
WALTHAM, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the pricing of its initial public offering of 12,251,578 shares
GlobeNewswire · 09/16 23:00
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DYN. Analyze the recent business situations of Dyne Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Executive Director/Director
Jason Rhodes
President/Chief Executive Officer/Director
Joshua Brumm
Chief Operating Officer
Susanna High
Chief Scientific Officer
Romesh Subramanian
Vice President - Finance/Primary Contact
Gene Kim
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DYN
Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Dyne Therapeutics Inc stock information, including NASDAQ:DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.